Brief: TransCode Therapeutics Announces IRB Approval For FDA Cleared First-In-Human Clinical Trial
27/04/2023 12:31
April 27 (Reuters) - Transcode Therapeutics Inc
RNAZ.O :
* TRANSCODE THERAPEUTICS ANNOUNCES IRB APPROVAL FOR FDA
CLEARED
FIRST-IN-HUMAN CLINICAL TRIAL
* TRANSCODE THERAPEUTICS - RECEIVED APPROVAL FROM DANA
FARBER
CANCER INSTITUTE INSTITUTIONAL BOARD TO PROCEED WITH
FIRST-IN-HUMAN PHASE 0 CLINICAL TRIAL
* TRANSCODE THERAPEUTICS INC - PLANNED CLINICAL TRIAL IS TO
EVALUATE DELIVERY OF TRANSCODE'S LEAD THERAPEUTIC CANDIDATE,
TTX-MC138
Source text for Eikon: ID:nGNX6jQzb
Further company coverage: RNAZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transcode Therapeutics
See all newsBrief: TransCode Therapeutics Appoints John Tattory As Interim CFO
Brief: Transcode Therapeutics Appoints Dr. Anna Moore As Chair Of Scientific Advisory Board
Brief: Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash
Brief: Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026
Brief: Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors